180 related articles for article (PubMed ID: 14607458)
1. Aldosterone antagonism and myocardial infarction: from animals to man and back.
Solomon SD; Pfeffer MA
J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458
[No Abstract] [Full Text] [Related]
2. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Thohan V; Torre-Amione G; Koerner MM
Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
[TBL] [Abstract][Full Text] [Related]
4. Role of a selective aldosterone blocker in mice with chronic heart failure.
Wang D; Liu YH; Yang XP; Rhaleb NE; Xu J; Peterson E; Rudolph AE; Carretero OA
J Card Fail; 2004 Feb; 10(1):67-73. PubMed ID: 14966777
[TBL] [Abstract][Full Text] [Related]
5. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
Jacob MS; Tang WH
Curr Heart Fail Rep; 2011 Mar; 8(1):7-13. PubMed ID: 21207206
[TBL] [Abstract][Full Text] [Related]
8. Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
Ramaraj R
Am Heart J; 2009 Mar; 157(3):e13; author reply e17. PubMed ID: 19249404
[No Abstract] [Full Text] [Related]
9. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Pitt B
J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone in heart failure--a revived role for an old drug.
Bradley C
Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
[TBL] [Abstract][Full Text] [Related]
12. Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
Doggrell S
Expert Opin Pharmacother; 2003 Sep; 4(9):1605-7. PubMed ID: 12943490
[No Abstract] [Full Text] [Related]
13. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
Aaronson K
Health News; 2003 May; 9(5):4. PubMed ID: 12739453
[No Abstract] [Full Text] [Related]
14. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
[TBL] [Abstract][Full Text] [Related]
15. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Urabe A; Izumi T; Abe Y; Taniguchi I; Mochizuki S
Hypertens Res; 2006 Aug; 29(8):627-34. PubMed ID: 17137219
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
17. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Imanishi T; Ikejima H; Tsujioka H; Kuroi A; Kobayashi K; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2008 Mar; 51(3):734-41. PubMed ID: 18227404
[TBL] [Abstract][Full Text] [Related]
18. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
Schäfer A; Fraccarollo D; Hildemann SK; Tas P; Ertl G; Bauersachs J
Cardiovasc Res; 2003 Jun; 58(3):655-62. PubMed ID: 12798439
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of enalapril and spironolactone in hamsters with dilated cardiomyopathy.
Goineau S; Pape D; Guillo P; Ramée MP; Bellissant E
J Cardiovasc Pharmacol; 2003 Jan; 41(1):49-59. PubMed ID: 12500021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
